|Study Description:||The goal of this retreatment portion of the study is to study the safety of |
this drug and the effect, if any, SGN-CD19A may have on the disease.
SGN-CD19A is designed to attach to a protein called CD19 on the surface of
cancer cells and then release a poison that may cause the cells to die.
This is the first study using SGN-CD19A in humans.